GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (FRA:GXE) » Definitions » Debt-to-Revenue

Galapagos NV (FRA:GXE) Debt-to-Revenue : 0.04 (As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Galapagos NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €3.5 Mil. Galapagos NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €8.2 Mil. Galapagos NV's annualized Revenue for the quarter that ended in Dec. 2024 was €302.0 Mil. Galapagos NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.04.


Galapagos NV Debt-to-Revenue Historical Data

The historical data trend for Galapagos NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Debt-to-Revenue Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.12 0.09 0.04 0.04

Galapagos NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.04 0.05 0.04

Competitive Comparison of Galapagos NV's Debt-to-Revenue

For the Biotechnology subindustry, Galapagos NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Debt-to-Revenue falls into.



Galapagos NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Galapagos NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.479 + 8.243) / 275.649
=0.04

Galapagos NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.479 + 8.243) / 301.98
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Galapagos NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Galapagos NV Headlines

No Headlines